Chairman & CEO, BioMarin Pharmaceutical, Inc. SVP, US Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim, Executive Vice President Immunology Solutions & Head of US, UCB Biopharma SPRL. Latest: Equity anonymous, Feb 6, 2022 at 5:38 PM. Professor Anthony Chan is Li Shu Fan Professor of Clinical Oncology; Director of the Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute; Chief Director of Phase I Clinical Trial Centre and Associate Dean (External Affairs) at the Chinese University of Hong Kong. Coming to Invetech by way of Rolls Royce aviation where he designed jet engines, Richard is passi Manufacturing Engineer, Jet Engine Designer, Automotive Restorer. Amy Schulman is a healthcare investor and Managing Partner at Polaris Partners. This lets us find the most appropriate writer for any type of assignment. Email: [emailprotected]gilead.com. His group has a strong focus on lentiviral technology and gene-editing tools including TALENs and CRISPR/Cas reagents for novel therapeutic applications. She serves on the Editorial Boards for several scientific journals, including Molecular Therapy, Cytotherapy, Molecular and Cellular Therapies. For the past decade, Darren led Lillys global business development efforts, retiring in 2019 as senior vice president of corporate business development. He joins Tessa from Takeda Pharmaceuticals, where he served as Senior Vice President, Asia Pacific, leading the transformation of Takeda across 10 markets enhancing the focus on rare and genetic diseases, oncology, and vaccines, based in Singapore. A*STAR oversees 18 biomedical sciences and physical sciences and engineering research entities primarily located in Biopolis and Fusionopolis. Dr Houot is a board member of the scientific committee for the Lymphoma Study Association (LYSA), member of the Committee on Translational Research (Early drug development) of the LYSA, and member of the EHA-SWG on Immunotherapy. Prior to joining Tessa, Mr. Cheung served as EVP and CFO at Apollomics Inc. from 2019 to 2022 where he led the efforts to complete a Series C round, and was CFO at KBP Biosciences Inc. in 2018. To be considered for a BIO Board seat, a candidate typically has this type of affiliation with a BIO member company. She served as Chair of the Cancer Immunotherapy Steering Committee of the American Association for Cancer Research (AACR) and was elected as a member of the Royal Society of Canada. Dr. Zamarin received his M.D. Got It. Chief Executive Officer, Neurocrine Biosciences, Inc. Chief Operating Officer, Alnylam Pharmaceuticals, Inc. President of Pharmaceuticals, Americas Region, Bayer Corporation, President, Corporate Affairs and Global Patient Relations, Grifols, SVP; President of Lilly Immunology; President of Lilly USA and Chief Customer Officer, Eli Lilly and Company. He completed his postdoctoral training in the Department of Immunology at the Scripps Clinic and Research Foundation in La Jolla, California. Dr. Ohashi received her Ph.D. from the University of Toronto with Dr. Tak Mak, and did her post-doctoral training at the University of Zurich with the Nobel Laureate Dr. Zinkernagel, and Dr. Hans Hengartner. PharmaTimes Media Ltd. Kite Pharma Anonymous board for Kite Pharma. Below is a synopsis of our discussion. He also co-founded several biotechnology companies and was a senior R&D executive with Pharmacia and Merck Research Laboratories. The proprietary platform created by Refuge is a synthetic biology system that uses an expression modulation strategy to repress or activate transcription of target genes, and early pre-clinical data suggests a potential for this platform to regulate target antigen-dependent gene expression as a means of improving both the efficacy and safety of first-generation CAR T-cell therapies. He graduated with an MBA from Trier University, Germany, and attained a Chinese Language Degree from Sun Yat-Sen University, Guangzhou, China. Among many projects, Ian has been the leading light of our RoHS offeringa role that calls for Electronics Engineer, Author, Antiques Collector. Our global headquarters are in Singapore, where we are building our own state-of-the-art commercial manufacturing facility. Dr. Tak Mak is a Foreign Associate of the National Academy of Sciences (USA) as well as a Fellow of the Royal Society of London (UK). It is a leading global institution with initiatives that bring basic science, translational, and clinical researchers together across disciplines and specialties to discover fundamental insights into human health and disease. During Lillys 145-year history, the two largest deals the $8 billion acquisition of Loxo Oncology and the $13 billion spin-out of Elanco Animal Health occurred during Darrens leadership. President and CEO, Vivace Therapeutics, Inc. President & Chief Executive Officer, Ardelyx Inc. Chairman, President and CEO, First Wave BioPharma, Inc. Davids experience, customer focus and passion for Seligs business make him well prepared to lead Seligs Sales and Marketing organization. Amid rising prices and economic uncertaintyas well as deep partisan divisions over social and political issuesCalifornians are processing a great deal of information to help them choose state constitutional officers and From innovative start-ups to multinational corporations, we help you embrace your get-to-market imperatives swiftly transforming your ideas into revolutionary products and solutions. Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Her interests include understanding CD8+ T cell biology and mechanisms that regulate anti-tumor immunity. He has been an associate editor (Hemato-oncology) for the European Journal of Cancer since 2015, and the co-founder and secretary of the French Society for Immunotherapy of Cancer (FITC). Kite a Gilead Company has entered into an exclusive, worldwide licence agreement with Refuge Biotechnologies (Refuge), a synthetic biology company for cancer immunotherapy. Professor Waseem Qasim is Professor of Cell and Gene therapy at the University College London Institute of Child Health. BIO now offers on-demand online classes that can be taken anywhere, anytime and at your own pace. In general, BIO Board candidates should be the CEO or Chairman of the Board of a research and development (R&D) focused biotechnology company, but certain Governing Boards have alternative criteria, especially for larger companies. Gilead Acquires Kite Pharma. Dr Josep Tabernero is Head of the Medical Oncology Department at the Vall dHebron University Hospital in Barcelona, and Director of the Vall dHebron Institute of Oncology (VHIO). Descubra cmo SUSE Rancher impulsa la estratega de Continental, creando eficiencia, manteniendo los mas altos estandares de calidad y mejorando la innovacin. Vea lo que est sucediendo en todo el mundo, Aumentar disponibilidad, eficiencia e innovacin, Plataforma optimizada y con gran capacidad de recuperacin para bases de datos y aplicaciones SAP, Solucin de gestin de infraestructura de cdigo abierto para operaciones de TI y DevOps de la empresa, Lightweight Kubernetes built for Edge use cases, Ultra-reliable, immutable Linux operating system, Reduccin de latencias del sistema y aceleracin de tiempos de respuesta, Despliegue y administre sus soluciones SAP de la manera ms fiable y sencilla del mercado, Transforme productos esenciales, desde automviles hasta dispositivos mdicos, en productos inteligentes y logre la excelencia en su sector, Acceso directo a un equipo premium designado, Mantener la versin de producto existente, Asistencia para plataformas comunes de Linux, Paquetes de la comunidad para SUSE Linux Enterprise Server, Inicio de sesin en el portal de partners de SUSE. Our focus unites the world-class experts we have brought together across cell and gene therapy, rare disease, clinical development and manufacturing. Tessa has established a Joint Lab with IMCB leveraging on IMCBs platform research capabilities, state of the art equipment and scientific networks, to collaboratively create novel T cell therapies for a wide range of cancers. Prior to joining Tessa, Dr. Horak was Head of Global R&D and Chief Scientific and Medical Officer at Symphogen, a clinical-stage antibody company, and President of R&D at Enzon Pharmaceuticals, Inc. Dr. Horak has also held a number of senior research leadership positions in various pharmaceutical companies as well as at the National Cancer Institute (NCI). IP Counsels Committee Conference November 14-16, 2022 | Boston, MA . President, Chief Executive Officer and Director, Agency for Science, Technology and Research. Prior to that, she was Senior Director, Clinical Research Oncology at Pharmacia and Pfizer, where she designed and conducted Phase I through Phase III clinical trials investigating solid tumor treatments in the metastatic and adjuvant settings. Were innovators, creators, problem-solvers and collaborators. Dr. Tabernero is currently President (2018 2019) of the European Society for Medical Oncology (ESMO) and an Executive Board and Council Member. Dr. Weiner also serves as Director of the MedStar Georgetown Cancer Institute, a cancer service line serving patients in the Washington, D.C., and Baltimore metropolitan areas. One is Azure, a leading cloud platform (ie a network of data centres and cloud computing F:+44 (0)20 7240 4479, Get the latest pharma news delivered to your inbox. Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry. degree from the University of Lyon (France) and a Ph.D. from the University of Rennes (France) on immunostimulatory antibodies in lymphoma. Tessa is developing a unique and potentially transformational allogeneic CD30-CAR EBVST platform capable of targeting a broad range of cancers. He holds the Francis L. and Charlotte G. Gragnani Chair and is Professor of oncology and Chair of the Department of Oncology at Georgetown University Medical Center. Join us! He is known for his laboratory and clinical research focusing on new therapeutic approaches that mobilize the patients immune system to fight cancer using monoclonal antibodies and other modalities of therapy. Baylor is a key strategic partner for Tessa. Prior to Takeda, Thomas held the position of Vice President, Oncology at GlaxoSmithKline (GSK) for its Intercontinental & Emerging Markets business, where he was assigned to develop the business strategy for Asia & Emerging Markets, including Access Strategy and Commercial structure design. Where to Next in Cell Therapy Manufacturing? University of North Carolina (UNC) Lineberger is one of the select academic centers in the United States with the scientific, technical and clinical capabilities to identify novel tumor targets and develop innovative CAR-T immunotherapy for patients. Revieve, a personalized digital brand experience company working with global brands, retailers and digital services providers in the beauty, skin, health, and wellness categories, has appointed Irina Mazur as chief product officer to support Revieves continued expansion in delivering personalization at scale to beauty consumers, brands, and retailers in North America. We share a passion for science, a commitment to teamwork and, above all, dedication to families and individuals living with genetic diseases. Darren Carroll is a Partner at Polaris Partners where he focuses on investing in therapeutics and healthcare technology companies. Full-service and future-ready. Dr. Ando brings to Tessa over 35 years of experience as one of the most accomplished and respected leaders in the global pharmaceutical industry. anonymous, Apr 27, 2019 at 3:07 AM. Kite is proud to have more than 300 authorized treatment centers (ATCs) where patients can receive CAR T-cell therapy across the globe, including more than 110 in the U.S. ATCs are independent facilities certified to dispense Kite CAR T therapies. What better environment than the Japanese automotive industry to learn and master Quality Policy Electrical Engineer, Quality Development, Soccer Player. Digital Journal is a digital media news network with thousands of Digital Journalists in 200 countries around the world. From March 1997 to October 1998, he served as an Acting Chief of NCIs Investigational Drug Branch, Cancer Therapy Evaluation Program. Get the latest news and analysis in the stock market today, including national and world stock market news, business news, financial news and more His current research focuses on identifying and therapeutically exploiting mechanisms employed by malignant cells to combat immune destruction. First-generation autologous CAR T-cell therapies have dramatically changed outcomes for people with certain blood cancers yet more work needs to be done to reach additional patients. Heslop and Brenner, was the first to demonstrate that antigen-specific T cells generated in the laboratory could prevent and cure viral-associated malignancies in humans following hematopoietic stem cell transplantation. Darren currently represents Polaris on the board of Noema Pharma and August Bioservices. Dr. Rooney has published over 200 peer reviewed articles on immunotherapies for virus and non-virus-associated malignancies and diseases. The invetech site works on all modern browsers with legacy support back through Internet Explorer 9. Schulman currently serves as Executive Chair of SQZ Biotech, as well as Lyndra Therapeutics where she was a co-founder and the companys initial CEO. Tiene comentarios acerca del sitio web? Accelerating a BIO-Revolution through global partnerships, collaboration, and thought leadership. Opportunities for women, Black and other minority populations in the growing Bio-economy. Before joining MD Anderson, Dr. Draetta served as Chief Research Business Development Officer and Deputy Director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute. Key Findings. Our focus unites the world-class experts we have brought together across cell and gene therapy, rare disease, clinical development and manufacturing. Learn about our mission, vision, values and priorities, Find out about BIO's programs & initiatives, Meet BIO's Senior Leadership and Board of Directors, Get to know the outstanding people and companies BIO supports. CD30 is a well validated lymphoma target with homogenous expression in Classical Hodgkin Lymphoma and multiple subsets of non-Hodgkin Lymphomas. Chairman & CEO, Amicus Therapeutics, Inc. Chief Executive Officer, AquaBounty Technologies, Inc. Executive Vice President and Chief Commercial and Operations Officer, Vertex Pharmaceuticals Incorporated, Senior Vice President, Government Affairs, Genentech, A Member of the Roche Group, President & Head of US Commercial Business, Bristol Myers Squibb Company. Dr. Siu was the recipient of the US NCI Michaele C. Christian Award in Oncology Drug Development in 2010 and has served on various committees of highly-recognized international oncology societies. The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media. Dr. Zamarin has received various awards for his work, including the 2014 Bladder Cancer Awareness Network Young Investigator Award, 2013 Conquer Cancer Foundation ASCO Young Investigator Award, the Damon Runyon Foundation Fellowship Award as well as the Ovarian Cancer Research Fund Liz Tilberis Early Career Award in 2017. President & CEO, Nkarta Therapeutics, Inc. President & Chief Executive Officer, Cerevast Medical, Inc. Head of Global Oncology Patient Value, Policy and Access, Takeda Oncology, President & CEO, Global Blood Therapeutics. Moreover, Refuge will retain all rights and programmes related to solid tumour indications. St. Jude Childrens Research (St Jude) Hospital leads the way the world understands, treats and cures childhood cancer and other life-threatening diseases, by advancing cures, and means of prevention for paediatric catastrophic diseasesthrough research and treatment. She serves on the Board of Directors of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Mount Sinai Hospital, and served as a Senior Lecturer at Harvard Business School. in Genetics from the University of East Anglia in England. Co-Founder, President, CEO & Director, Allievex Corp. CEO, President, Co-Founder, Asklepios BioPharmaceutical, Inc. (AskBio), President, CEO & Director, CODA Biotherapeutics. His expertise also includes working with CMOs as a customer and as a provider. Better joined Kite in Jan 2013 where he brought experience in biologics CMC; upstream, downstream, analytical and drug product development; GMP manufacturing; commercial manufacturing support; technology transfer; contract manufacturing; and regulatory interactions. BACK TO MAIN MENU Company Statements Kite Receives U.S. Food and Drug Administration (FDA) Orphan Drug Designation for KITE-222 for Acute Myeloid Leukemia Kite Launches CAR T-cell Therapy Operations in Brazil, Singapore and Saudi Arabia Kite Announces U.S. FDA Clearance of Investigational New Drug Application for Kite-363, a Dual-Targeting CAR T-Cell Therapy She has previously served on the Board of Directors for the American Society of Clinical Oncology (ASCO) and as a member of AACRs Nomination Committee. You can obtain detailed information about the use of cookies on our website by clicking on "More information. We work with some of the most well-recognized names in healthcare. Tessa is collaborating with Baylor on multiple fronts, including on our TT11 cHL Pivotal trial, early phase trials testing new therapies and co-development of novel allogeneic platform. If you are interested in nominating yourself or another person to be a candidate and potentially fill a vacancy on the BIO Board, please inquire here to learn more about the BIO Board nomination process: If you have any questions about the BIO Board of Directors, please contact Peter McHugh at pmchugh@bio.org. Dr. Tak Mak is the Director of the Campbell Family Institute at the Princess Margaret Cancer Centre and a University Professor in the Departments of Medical Biophysics and Immunology at the University of Toronto. Our global writing staff includes experienced ENL & ESL academic writers in a variety of disciplines. In addition to Griffins appointment, BJ Radek has been promoted to director, sales Americas. Kite a Gilead Company has entered into an exclusive, worldwide licence agreement with Refuge Biotechnologies (Refuge), a synthetic biology company for cancer immunotherapy. Executive Vice President, General Counsel and Secretary, Regeneron Pharmaceuticals, Inc. Head of Global Oncology Patient Value, Policy and Access, Takeda Pharmaceuticals America, Inc. Executive Vice President and Chief Operating Officer, Genmab, Regional Head, Canada and Latin America, GlaxoSmithKline, SVP, Global Healthcare Policy & External Affairs, CSL Behring, EVP, Chief Medical Officer, Horizon Therapeutics plc, EVP & Head of Sanofi Genzyme, Sanofi Genzyme. Dr. Rooney is a Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, and Pathology and Director of Translational Research Laboratories of the Center for Cell and Gene Therapy at Baylor College of Medicine. David Griffin joined Selig in 2020 after spending 15 years with dispensing and packaging provider Aptar. Dr. Horak brings more than 20 years of experience in the global pharmaceutical industry, predominantly focused on oncology drug development, and is a board-certified medical oncologist. Selig Groups Bill Radek, executive vice president, global sales and marketing, will retire at the end of the year. Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer. He has also been a certified director of corporate governance from the executive program of the UCLA John E. Anderson Graduate School of Management since 2005. Quiere transformar sus procesos empresariales internos y su infraestructura de TI para competir con mayor eficacia en la economa digital actual? Leatherhead Trodelvy Spoilage Replacement Program. She is the Principal Investigator of a Phase I cooperative agreement UM1 award (2014-2020) sponsored by the United States National Cancer Institute. E:subscriptions@pharmatimes.com BIO Member and group discounts available! Prior to that, Thomas served as Chairman and General Manager for GSK in China, and as General Manager of GSK Taiwan. Tessa is leading the way in CD30 targeting using cell therapy. In addition, his group was also the first to define the functions of CTLA-4. A footnote in Microsoft's submission to the UK's Competition and Markets Authority (CMA) has let slip the reason behind Call of Duty's absence from the Xbox Game Pass library: Sony and Copyright PharmaTimes Media Limited 2022, International Clinical Researcher of the Year, Clinical Researcher of the Year - The Americas, Aelix and Gilead announce results of HIV infection candidate, New device launched for diagnosing prostate cancer, UK government to cut cost of repeatable HRT prescriptions, Recent Ozempic, Victoza data promising for diabetic kidney disease, GSKs anaemia drug gets FDA advisory committee support for patients on dialysis, AstraZenecas Farxiga data shows widespread undiagnosed chronic kidney disease. Password requirements: 6 to 30 characters long; ASCII characters only (characters found on a standard US keyboard); must contain at least 4 different symbols; In October, Gilead Sciences GILD shelled out $11.9 billion for Kite Pharma, marking its biggest acquisition ever. from Mount Sinai School of Medicine. Cell Therapy Application Scientist, Foodie, Outdoor Enthusiast. Dr. Gruia previously served as Chief Development Officer at Ichnos Sciences, where she oversaw several key functions including Regulatory Sciences, Clinical Operations, Clinical Pharmacology, Biostatistics and Drug Safety. We share a passion for science, a commitment to teamwork and, above all, dedication to families and individuals living with genetic diseases. As your end-to-end partner, we accelerate your path to commercialization through the design, development and manufacture of life-changing diagnostic products and cell therapy solutions. Mr. Cheung was appointed CFO of Tessa Therapeutics in April 2022. Para obtener informacin sobre asistencia tcnica, visite Asistencia. This lets us find the most appropriate writer for any type of assignment. He currently serves as Chairman of the Board for Eyepoint Pharma, Nouscom & Nanexa AB and is a member of the Board for Selecta Biosciences, . Dr. Weiner is an active member of the American Society of Clinical Oncology and the American Association for Cancer Research (AACR), and founded the AACR Cancer Immunology Working Group. He is recipient of the 2019 AACR Distinguished Public Service Award. Mr. Cheung has been a California certified public accountant since 1994. Kite is working on the next generation of cell therapies with the goal to improve upon the results we have today so more patients can benefit, said Francesco Marincola, global head of cell therapy research, Kite. Gilead Acquires Kite Pharma. Digital Journal is a digital media news network with thousands of Digital Journalists in 200 countries around the world. He is currently a Principal Consultant at Pharmafex Consulting, CMC Advisory Board Member at Nutcracker Therapeutics and core team member at Cell One Partners. A footnote in Microsoft's submission to the UK's Competition and Markets Authority (CMA) has let slip the reason behind Call of Duty's absence from the Xbox Game Pass library: Sony and Ch.B. Chair & Chief Executive Officer, Infinity Pharmaceuticals, Inc. Chairman & Chief Executive Officer, Versanis Bio. T:+44 (0)20 7240 6999 Sign up for the Good Day BIO Newsletter >. (844) 454-KITE. Prior to joining Polaris, Darren completed a 22-year career with the pharmaceutical firm Eli Lilly and Company in Indianapolis. Mr. Ng has been the CTO of Tessa Therapeutics since 2015 and is a member of the founding executive leadership team. BIOs WDDI Principles can be found at: https://www.bio.org/diversity. Learn more. Dr. Maks current research is focused on immune system cell functions and regulation, and the role of inflammation in the progression of autoimmune diseases and cancer. The Society of Cosmetic Chemists announced the winners of three prestigious awards being presented during the Societys 76th Annual Scientific Meeting & Showcase being held December 12-14, 2022, at the JW Marriott LA Live in Los Angeles, California.Maison G. deNavarre Medal Award.The Society's highest honor is awarded to David C. Steinberg in Con nosotros, tiene el poder de innovar en cualquier parte, desde el centro de datos hasta la nube, el permetro y ms all. Amy joined Polaris in 2014. Professor Chan obtained his MBBS in University College Hospital and Middlesex Joint School of Medicine in London and completed his postgraduate training in the U.K. at the Royal Marsden Hospital. Previously Dr. Ando was Senior Adviser to leading specialist healthcare investment group Essex Woodlands andis also the retired Chairman of the Board of global pharmaceutical company Novo Nordisk A/S. Dr. Sznol was previously Vice President of Clinical Affairs and Executive Officer at Vion Pharmaceuticals Inc. One is Azure, a leading cloud platform (ie a network of data centres and cloud computing Darren earned an AB in political science (summa cum laude), Masters in public administration, and JD in law from Syracuse University, where he held the University Fellowship, L.E.S. Dr. Weiner previously served as Chairman of the Medical Oncology Department and Vice President for Translational Research at Fox Chase Cancer Center in Philadelphia, and also served as Professor in the Department of Medicine at Temple University School of Medicine.